Catheter Ablation Chest X Ray — Cost, Top Hospitals & Success Rates | MyMedicPlus

Catheter ablation is a minimally invasive electrophysiology procedure that treats cardiac arrhythmias by delivering targeted energy (radiofrequency heat, cryoenergy, or pulsed electric field) through electrode catheters to create precise scar tissue (lesions) in the heart muscle that block or eliminate abnormal electrical circuits perpetuating the arrhythmia. The procedure is performed in a specialised cardiac electrophysiology (EP) laboratory under fluoroscopic and electroanatomical mapping guidance, with the patient under conscious sedation or general anaesthesia.

Catheters are introduced via the femoral veins (and occasionally femoral artery) in the groin and advanced under fluoroscopy to the heart chambers. A 3D electroanatomical mapping system (CARTO, EnSite X) creates a real-time three-dimensional image of the heart chambers with colour-coded voltage maps showing healthy tissue and scar. The mapping catheter identifies the origin or critical isthmus of the arrhythmia, the ablation catheter is precisely positioned, and energy is delivered — with radiofrequency (RF) ablation heating tissue to 50–60°C to create an irreversible lesion, and cryoablation cooling tissue to minus 40–60°C using a balloon catheter. Pulsed field ablation (PFA) — an emerging technique delivering microsecond electrical pulses — achieves cardiac cell death through electroporation while sparing adjacent oesophageal and pulmonary vein structures.

The most common indication is atrial fibrillation (AF), for which pulmonary vein isolation (PVI) — electrically disconnecting the pulmonary veins from the left atrium — is the cornerstone of ablation strategy. Other common indications include supraventricular tachycardia (SVT) subtypes, atrial flutter, ventricular tachycardia (VT), and Wolff-Parkinson-White syndrome.

Atrial fibrillation is the most common arrhythmia treated by catheter ablation. Pulmonary vein isolation for paroxysmal AF (intermittent episodes terminating spontaneously) achieves freedom from AF in approximately 65–75% of patients at one year without antiarrhythmic drugs, rising to 80–85% with repeat procedures. For persistent AF (lasting more than seven days), ablation outcomes are somewhat lower and may require additional substrate modification beyond PVI. The CABANA and CASTLE-AF trials demonstrated superiority of catheter ablation over antiarrhythmic drugs for AF in reducing AF recurrence and — in heart failure patients — all-cause mortality.

Supraventricular tachycardias (SVT) including atrioventricular nodal re-entrant tachycardia (AVNRT — the most common SVT), atrioventricular re-entrant tachycardia using an accessory pathway (AVRT, Wolff-Parkinson-White), and atrial tachycardia are highly amenable to ablation with success rates of 90–98% and very low recurrence rates. Typical atrial flutter — caused by a re-entrant circuit around the tricuspid annulus — is treated by cavotricuspid isthmus (CTI) ablation with success rates above 95%. Ventricular tachycardia in patients with ischaemic cardiomyopathy or structural heart disease is addressed by ablation of reentrant scar-related circuits, reducing VT storm episodes and ICD shocks.

Ideal candidates for AF catheter ablation are patients with symptomatic paroxysmal or persistent AF who have failed one antiarrhythmic drug (or declined drugs), have no significant structural heart disease (normal or mildly impaired LV function), are in an early stage of disease (paroxysmal AF with relatively small left atrium below 5 cm diameter responds best), and are motivated to undergo a three-to-four hour invasive procedure under sedation or anaesthesia. Early rhythm control with ablation is now supported by evidence in newly diagnosed AF — the EAST-AFNET4 trial demonstrated that early rhythm control (within one year of diagnosis) reduces cardiovascular events compared to rate-control-first strategy.

Contraindications to AF ablation include presence of left atrial thrombus (detected by transoesophageal echocardiography or CT prior to ablation — anticoagulation must be therapeutic for at least three weeks before ablation if thrombus is absent), active systemic infection, severe uncontrolled hypertension (increases risk of haemorrhagic complications), pregnancy, severe mitral stenosis (which should be treated first), and patient refusal of anticoagulation (required for at least three months after ablation). For SVT ablation, essentially all patients with symptomatic documented SVT are candidates; the very high success rates and low complication rates make it appropriate even for young patients who prefer a cure over lifelong medication.

Radiofrequency ablation (RFA) is the most widely used energy source, using alternating current at 500 kHz to heat tissue and create irreversible lesions. For AF ablation, point-by-point RFA with a contact force-sensing ablation catheter (Biosense Webster ThermoCool SmartTouch, Abbott TactiCath) creates a continuous circular line of lesions around each pulmonary vein pair to achieve PVI. The CLOSE protocol — targeting contiguous lesions with defined contact force and ablation index targets — has improved first-pass isolation rates and durability.

Cryoballoon ablation (Arctic Front Advance Pro, Medtronic) uses a balloon catheter that occludes each pulmonary vein ostium and delivers cryoenergy to freeze and electrically isolate the vein. It is technically simpler for PVI, with equivalent one-year freedom from AF to point-by-point RF ablation in the FIRE AND ICE randomised trial. Pulsed field ablation (PFA) using the Farapulse (Boston Scientific) or Volt (Medtronic) system is the most significant recent innovation — delivering microsecond pulsed electric fields to achieve cardiomyocyte-selective ablation while sparing oesophagus, pulmonary veins, and phrenic nerve. PFA significantly reduces procedure time (average 60–90 minutes), eliminates oesophageal injury risk, and achieves PVI with comparable durability to RF ablation in the ADVENT and PULSED AF trials. For VT ablation, endocardial and epicardial mapping and ablation of scar-related re-entrant circuits is performed with RF energy, often with electrophysiological inducibility testing before and after ablation.

Catheter ablation for paroxysmal AF provides freedom from AF in approximately 65–75% of patients at twelve months after a single procedure without antiarrhythmic drugs. With repeat procedures (performed in approximately 20–30% of patients), twelve-month success rates increase to 80–90%. The CABANA trial demonstrated significant superiority of AF ablation over drug therapy for the per-protocol population in AF recurrence reduction. In patients with heart failure and AF, the CASTLE-AF trial demonstrated that ablation reduced all-cause mortality and hospitalisation compared to rate and rhythm control medications.

For SVT ablation, success rates are outstanding: AVNRT ablation achieves permanent cure in 95–98% of patients with a recurrence rate below 3–5%. AVRT (WPW) ablation achieves cure in 90–95% with low recurrence. Atrial flutter CTI ablation is curative in over 95% of typical flutter cases. These high success rates make ablation the preferred treatment over long-term antiarrhythmic drugs for symptomatic SVT in most international guidelines, including ACC/AHA and ESC. For VT ablation in ischaemic cardiomyopathy, the VANISH and CALYPSO trials demonstrated reduction in ICD shocks and VT storm compared to escalating drug therapy, though long-term mortality benefit requires further investigation.

Catheter ablation for AF is an invasive procedure with recognised complication rates. Vascular access complications at the femoral groin site — haematoma, pseudoaneurysm, arteriovenous fistula — occur in approximately 1–3%. Pericardial effusion or cardiac tamponade from inadvertent perforation of the thin left atrial wall occurs in approximately 1–2% of AF ablations and requires immediate pericardiocentesis; rarely, emergency surgery. Transient or permanent cerebral ischaemia (stroke or TIA) occurs in approximately 0.5–1.5% of AF ablations, reflecting the thromboembolic risk of left atrial manipulation; continuous heparinisation during the procedure and therapeutic anticoagulation for at least three months after ablation are essential preventive measures.

Oesophageal injury — from collateral thermal damage to the posterior oesophagus that lies immediately behind the left atrium during RF ablation — ranges from asymptomatic mucosal erythema (common) to rare but potentially lethal atrio-oesophageal fistula (1 in 1,000–2,500 procedures), which presents two to four weeks post-ablation with fever, neurological symptoms, and mediastinitis. Pulsed field ablation (PFA) essentially eliminates this risk, which is one of its major clinical advantages. Phrenic nerve palsy — typically from right phrenic nerve injury during cryoballoon ablation of the right superior pulmonary vein — occurs in 2–5% of cryoablations and resolves in the majority within six to twelve months. Pulmonary vein stenosis — narrowing of the isolated pulmonary veins from thermal injury — occurs in below 1% with modern large-balloon and contact force RF techniques.

After catheter ablation, patients are observed in a monitored cardiac recovery area for four to six hours before discharge (same-day discharge for SVT ablation) or overnight (AF ablation, complex VT ablation). Groin compression is maintained for two to four hours to prevent haematoma; ambulation commences once haemostasis is confirmed. Anticoagulation with a direct oral anticoagulant (apixaban, rivaroxaban) is mandatory for at least three months after AF ablation regardless of perceived ablation success, as asymptomatic AF recurrences may occur early in the recovery period.

A blanking period of three months after AF ablation is recognised — arrhythmia recurrences in the first three months may reflect inflammatory reactions to ablation rather than true treatment failure and do not necessarily predict long-term outcome. Anti-arrhythmic drugs continued during this blanking period are typically tapered at three months. Holter monitoring and patient-recorded ECG (KardiaMobile) are used to document rhythm status. A follow-up visit at three months assesses anticoagulation decisions (whether to continue beyond three months for AF recurrence risk), rhythm outcome, and need for repeat ablation. Return to driving is typically two to three days after uncomplicated SVT ablation and one to two weeks after AF ablation.

Catheter ablation is an expensive procedure requiring a specialised EP laboratory, advanced mapping systems, and single-use catheters. In the United States, AF ablation costs USD 30,000–60,000 including EP laboratory, catheters, sedation, and hospitalisation; SVT ablation costs USD 20,000–40,000. UK NHS provides catheter ablation for symptomatic arrhythmias on waiting lists; private UK ablation costs GBP 10,000–25,000. In India, leading cardiac centres including Fortis Escorts Heart Institute (Delhi), Apollo Hospitals, and Narayana Health perform AF ablation for USD 5,000–12,000 and SVT ablation for USD 3,000–8,000 — savings of 70–85% versus US prices.

Thailand (Bangkok Heart Hospital, Bumrungrad) charges USD 10,000–20,000 for AF ablation; Turkey (Acibadem, Florence Nightingale Cardiac) USD 8,000–15,000; Poland EUR 7,000–14,000. International patients should ensure the centre has a dedicated cardiac electrophysiology programme with experienced operators performing high-volume ablation (above 200 AF ablations per year per operator for best outcomes), a modern 3D mapping system (CARTO or EnSite), and availability of pulsed field ablation technology if indicated. Structured follow-up arrangements post-ablation — either through the international centre for the first three months or with a local cardiologist — must be planned before travel.

Antiarrhythmic drug therapy — using sodium channel blockers (flecainide, propafenone — for AF without structural heart disease) or potassium channel blockers (amiodarone, sotalol, dronedarone) — remains the primary alternative to ablation for rhythm control in AF and is guideline-recommended as a first-line option in many patients. However, antiarrhythmic drugs have significant side effects (amiodarone: thyroid, pulmonary, hepatic, neurological toxicity), limited long-term efficacy (approximately 30–50% freedom from AF at one year for most agents), and require ongoing monitoring. Rate control with beta-blockers, rate-limiting calcium channel blockers, or digoxin — without attempting rhythm control — is an accepted strategy for older patients with minimal AF symptoms and acceptable ventricular rate control.

For SVT, vagal manoeuvres (Valsalva, carotid sinus massage) and intravenous adenosine terminate acute SVT episodes. Long-term prevention with beta-blockers or calcium channel blockers reduces frequency but is not curative. For atrial flutter, electrical cardioversion restores sinus rhythm acutely; antiarrhythmic drugs prevent recurrence with modest efficacy. CTI ablation is highly curative and is the preferred long-term treatment for typical atrial flutter. For VT, implantable cardioverter-defibrillator (ICD) implantation provides lifesaving shock therapy for ventricular fibrillation and VT but does not prevent VT episodes — ablation reduces VT burden and ICD shocks.